Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu Pandemic mRNA vaccine in healthy adults
NCT06382311Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2024
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of flu pandemic mRNA vaccine in influenza (3 arms), sponsored by GSK. Primary endpoints: Percentage of participants with solicited administration site events at 4 weeks, Percentage of participants with solicited systemic events at 4 weeks and 2 more. Started Apr 2024; status: completed.
02
Drugs
flu pandemic mRNA vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06382311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06382311.